thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
The GABA transporter 1 (GAT-1) and GABA reuptake inhibitor tiagabine (Gabitril) is approved and clinically used as an anticonvulsant. It has also been used off-label in the treatment of anxiety disorders and other conditions. The drug increases γ-aminobutyric acid (GABA) levels in the brain and has been found to improve sleep, including by increasing slow wave sleep (deep sleep). In addition, tiagabine has been reported to make sleep feel more restorative and to improve some cognitive outcomes. The drug has an elimination half-life of 5 to 8 hours. While tiagabine may have hypnotic effects, off-label use is discouraged as it has been associated with new-onset seizures in people without epilepsy.
=== Mass spectrometer === Quadrupole, magnetic sector, and time-of-flight (TOF) are the three mass spectrometers (MS) used in SIMS. For SSIMS, the primary requirement is low primary-ion flux density, which results in extremely low secondary ion yield (10−3 – 10−8 atoms/cm3). Hence, there is a need to collect almost all the secondary ions. High transmission (0.5–1) of TOF maximizes the sensitivity (104 times that of quadrupole MS). Parallel detection together with reasonable mass resolution and high mass range (m/z > 103) are among its other major advantages. Ions are accelerated to a given potential so that they have the same kinetic energy, resulting in ions of different mass:charge (m/e) ratio having different velocities. These ions then pass through a region of field-free space in the flight tube, and spread out in time, with the higher-mass ions arriving later at the end of the flight tube, where a time-sensitive detection system produces a mass spectrum. The primary ions are pulsed into short bursts of less than 10 ns (the time scale of secondary-ion emission after impact is negligible (<10−12 s)). The primary beam is pulsed by a rapid deflection across a small aperture or by off-axis deflection, followed by a curved magnetic field to compress the pulse in space. There are very high accelerating fields at the sample (high extraction voltage and small (mm) extraction gaps) to reduce the initial energy spread of the secondary ions. Some TOF systems further compensate for this energy spread by using nonlinear flight tubes.
== History == The company was founded in 1929 by Dharampal Sugandhi in Chandni Chowk, Delhi, as a perfumery business producing incense sticks, rose water, and tobacco products. In 1958, Satyapal Sugandhi introduced the BABA tobacco brand. During the 1980s, the group diversified into packaged foods with the launch of Catch Salt & Pepper (1987), followed by Catch Natural Spring Water in 1999. The group's subsequent launches included confectionery products under brands such as Rajnigandha, Pass Pass, and Pulse Candy. In 2019, the DS Group acquired an 11–18% stake in the Switzerland-based Lalique Group . In 2023, it introduced the Swiss chocolate brand Läderach to India and acquired the Indian confectionery brand LuvIt.
Sources: en.wikipedia.org
protein purification Any process by which one or more specific proteins are isolated from a heterogeneous mixture such as whole cells or tissues, usually by first separating the protein and non-protein components of the mixture and then by separating the protein(s) of interest from all other non-target proteins. Purification is often necessary in order to remove contaminants that might interfere with the study of the protein of interest's structure, function, and interactions with other molecules. A wide variety of isolation techniques exist, most of which exploit differences in the size, solubility, binding affinity, enzymatic activity, or other physico-chemical properties of the separated components. Some techniques tend to destroy higher-order structure and thus are only useful for identification of the protein's primary amino acid sequence, while others are designed to preserve the structure and function of the protein's native state.
=== Importance of kinetic effects === Another limitation of MHD (and fluid theories in general) is that it depends on the assumption that the plasma is strongly collisional (this is the first criterion listed above), such that the collision time scale is shorter than the other characteristic time scales in the system, and the particle distributions are Maxwellian. This is usually not the case in fusion, space, and astrophysical plasmas. When this is not the case, or when interest lies in smaller spatial scales, it may be necessary to use a kinetic model that properly accounts for the non-Maxwellian shape of the distribution function. However, because MHD is relatively simple and captures many of the important properties of plasma dynamics, it is often qualitatively accurate and is therefore often the first model tried. Effects that are essentially kinetic and not captured by fluid models include double layers, Landau damping, a wide range of instabilities, chemical separation in space plasmas, and electron runaway. In the case of ultra-high-intensity laser interactions, the extremely short time scales of energy deposition mean that hydrodynamic codes fail to capture the essential physics.
Department of Defense on human–animal bonding determined that there was an improvement and enrichment of life when animals were closely involved with humans. The study tested blood levels and noticed a rise in oxytocin in humans and animals which participated; oxytocin has the ability to lower stress, heart rate, and fear levels in humans and animals. Historically, animals were domesticated for functional use; for example, dogs for herding and tracking, and cats for killing mice or rats. Today, in Western societies, their function is primarily bonding. For example, current studies show that 60–80% of dogs sleep with their owners at night in the bedroom, either in or on the bed. Moreover, in the past the majority of cats were kept outside (barn cats) whereas today most cats are kept indoors (housecats) and considered part of the family. Currently, in the US, for example, 1.2 billion animals are kept as pets, primarily for bonding purposes. In addition, as of 1995, there were over 30 research institutions looking into the potential benefits of the human–animal bond.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.